In 2026 ZS displaced an SFE-focused MR provider and now runs one of the industry’s largest portfolio-wide SFEA programs. The same consolidation, the same kind of incumbent, and the call-log approach we are proposing here already running across that portfolio.
SAME CHALLENGE
Fragmented SFE studies
SAME KIND OF INCUMBENT
An SFE-focused MR provider
ALREADY LIVE
Call-log based recruitment
It’s a welcome change. When you move from one supplier to another, you want the process to be seamless. Thanks, ZS.
You’ve made this entire process an easy lift.
We will take these findings to all Regional Directors.
PROJECT NEXUS
One unified SFEA program that creates consistency while preserving flexibility by brand
Nine studies run in silos today, which limits comparability, efficiency and consistent decision-making. NEXUS brings them onto a common foundation through three actions.
OPTIMIZE
Consistency at scale, flexibility by brand
A standardized core of the survey with aligned methods and definitions, plus brand and TA modules built with each MR lead. Every brand keeps what makes its study useful; leadership gets results that compare.
UNDERSTAND
Credible signals, interpreted in context
Feedback anchored to actual JJIM calls wherever feasible, interpreted by teams who already work on these brands, and connected to other data sources rather than read in isolation.
ACT
Insights brand teams can act on
Findings translated into clear priorities for coaching, call planning and message execution, grounded in ZS's sales force effectiveness practice and our current field work with JJIM brands.
WHAT SETS ZS APART
Any established partner can run the studies. Four things decide whether they change anything
DELIVERABLES
What actually lands on your desk
Monthly brand scorecards, an interactive dashboard, quarterly brand reports and a cross-portfolio executive readout. Below are the real output formats from our current program, with illustrative multiple myeloma data.
Multiple Myeloma SFEA KPI Scorecard, Q1 2027
Brand-level · monthly one-pager · 6 to 8 core KPIsIllustrative
TECVAYLI (JJIM)ELREXFIOLYNOZYFIC
All brands reported for the same period (Q1 2027: January to March). Weighting. SOV, reach and frequency: all data points weighted on call vs non-call weights. Other metrics: all data points other than TECVAYLI weighted on call vs non-call weights; TECVAYLI data reported among only those present in the J&J call log who recalled a J&J interaction. 1. Based on interactions in the past 1 month. 2. Based on most recent interaction.
ZS Kural interactive KPI dashboard
Brand and portfolio views · monthly refresh · at no added cost to JJIMIllustrative · interactive
This one is live. Pick a KPI on the left, switch the practice setting, or ask Kural a question in plain language.
KPI
Practice setting
Ask Kural
Plain-language questions, answered from the study data with citations and sample sizes. Pick one of these, or type your own.
Pick a question above, or type your own.
Everything above is live: select a KPI on the left, change a data cut, or ask a question. De-identified respondent-level data also feeds JJIM’s existing dashboards at no added cost. Answers here are scripted for demonstration; in the live environment each one queries the study database with full traceability back to the underlying respondents.
Key sales representative performance drivers
Quarterly brand report · Q1 2027, January to MarchIllustrative
Rep performance on key attributes
% of HCPs rating 6 or 7 on a 7-point scale, where 1 = performed poorly and 7 = performed extremely well. Based on most recent interaction.
J indicates DARZALEX (JJIM) is statistically significantly higher than SARCLISA at 95% C.I. ZS Benchmarks reflect industry performance based on aggregated, normalized data from multiple ZS SFE project reports spanning various products, indications and therapy areas. Weighting. All data points other than DARZALEX are weighted on call vs non-call weights; DARZALEX data reported among only those present in the J&J call log who recalled a J&J interaction.
Executive readout, multiple myeloma
Q1 2027, January to March · n=120 completes · DARZALEX vs SARCLISAIllustrative
Reach71%SARCLISA 62%
Frequency1.8SARCLISA 1.5
Call recall79%of called HCPs
Likelihood to increase Rx56%SARCLISA 49%
THE HEADLINE
DARZALEX leads SARCLISA on every engagement metric this quarter. The one place it does not lead the market is practice support, the lowest rated attribute and the only one sitting level with the ZS benchmark.
1
71% vs 62%Leads on reach and interaction frequency (1.8 vs 1.5 per reached HCP), with interactions predominantly in person
Sustain the reach and frequency advantage over SARCLISA
2
79% recallStrong call memorability among HCPs the field actually reached
Keep core DARZALEX FASPRO messaging consistent across interactions to build on it
3
68% vs 63%Rated higher on overall quality, call to action (39% vs 31%) and likelihood to increase prescribing
Reinforce clear calls to action, compliantly, with high-potential HCPs
4
6 of 6 attributesReps lead on every attribute, widest on credible information (78% vs 66%) and clear message delivery (77% vs 61%)
Feed the findings into commercial effectiveness improvement and field training
5
PRIORITY70%, at benchmarkPractice support is the lowest-rated attribute; HCPs want sequencing guidance and real-world outcomes
Strengthen access, reimbursement and onboarding support, and equip reps with sequencing guidance and real-world evidence
Every readout closes with named JJIM owners and dates against each action, tracked to the next wave. Figures are illustrative.